Biotechnology company studies an efficacy and safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain
The clinical-stage biotechnology company Eliem Therapeutics (UK) Ltd is commencing recruitment for the clinical trial of the Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain.
The conditions are Diabetic Peripheral Neuropathic Pain, Diabetic Peripheral Neuropathy.
A new clinical trial is recruiting patients in the following locations: United States.
The trial officially began on the November 9, 2020 and is planned to complete on October 15, 2021.
The population that can be enrolled into this study includes:
- Participant is ≥18 and ≤75 years of age at the time of signing ICF.
- Participant has a diagnosis of type 1 or 2 diabetes mellitus.
- Participant has diabetic neuropathy of a symmetrical nature in the lower extremities for ≥6 months to ≤10 years.
- Participant reports at least moderate pain intensity.
- Participant onset of neuropathic pain is at least 3 months before the screening visit.
There are a number of conditions that do not allow participation, such as:
- Participant has pain that cannot be clearly differentiated from or that could interfere with the assessment of DPNP.
- Participant has neurologic and/or circulatory disorders that are unrelated to diabetic neuropathy.
- Participant has a history of hypoglycemia that disturbed consciousness or ketoacidosis that required hospitalization within the 3 months before screening.
- Participant has clinically significant and/or unstable renal, hepatic, hematologic, immunologic, inflammatory/rheumatologic, respiratory, or cardiovascular disease that would compromise participation in the study in the judgment of the investigator.
The full list of Inclusion/exclusion criteria can be viewed at the link below.
The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT04688671
